TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00753558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
Description: Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
Description: Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel.
Study: NCT03352986

Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients

Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients

Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients

Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients

Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients
Study: NCT01051414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 1200 mg, daily, 24 weeks
Study: NCT01380847

Intervention type: GENETIC
Intervention: mRNAs encoding genes
Description: investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
Study: NCT03352986

Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients

Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients

Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients

Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients

Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients

Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients

Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients
Study: NCT01748981

Intervention type: OTHER
Group type: OTHER
Intervention: Physical training
Description: Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls

Intervention type: OTHER
Group type: OTHER
Intervention: As usual
Description: Controls, not training
Study: NCT02882854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Patients will receive 1 mg of guanfacine to take orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
Study: NCT03911414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Description: Open-label Treatment with Omega-3 Fatty Acids + Inositol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Treatment with N-acetylcysteine
Description: Open-label Treatment with N-acetylcysteine
Study: NCT00129493

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group medical visits
Description: Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
Study: NCT00148889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation (DBS)
Description: Bilateral pallidal stimulation with an implanted DBS device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation (DBS)
Description: Bilateral pallidal stimulation with an implanted DBS device
Study: NCT02989129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
Study: NCT03981913

Intervention type: BEHAVIORAL
Intervention: Simon Task with high-density EEG recording
Description: The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected.

Intervention type: BEHAVIORAL
Intervention: Simon Task with high-density EEG recording
Description: The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected.
Study: NCT01654003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMIZED
Description: In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
Study: NCT01332292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate
Description: Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate
Description: Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
Study: NCT02401204

Intervention type: OTHER
Intervention: Longitudinal surveillance study
Description: Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected.
Study: NCT01621867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pGM169/GL67A
Description: 5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
Study: NCT04375176

Intervention type: DIAGNOSTIC_TEST
Intervention: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2
Description: Phenotypic and functional analysis of monocytes and NK cells
Study: NCT03634267

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study: NCT02301481

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: 45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery, preferred D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery, preferred D2 lymphadenectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Study: NCT02759991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hecolin
Description: 0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hepa-B
Description: 1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
Study: NCT02082106

Intervention type: OTHER
Intervention: Alpine skiing

Intervention type: OTHER
Intervention: cross country skiing

Intervention type: OTHER
Intervention: Indoor training (cycling)
Study: NCT03475329

Intervention type: OTHER
Intervention: adenotonsillectomy
Description: adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy

Intervention type: OTHER
Intervention: adenotonsillectomy
Description: adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
Study: NCT03023163

Intervention type: OTHER
Intervention: Longitudinal
Description: Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.

Intervention type: OTHER
Intervention: Longitudinal
Description: Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
Study: NCT02994693

Intervention type: DEVICE
Intervention: OFDI capsule imaging
Description: Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
Study: NCT02533726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Turning
Description: Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Practices
Description: Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Sensor
Description: A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Sensor
Description: A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
Study: NCT04608734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Description: The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal midazolam
Description: Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
Study: NCT02845531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: Implantable Cardioverter Defibrillator and Optimal Medical Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Study: NCT03527719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village-doctor-led multifaceted intervention
Description: * Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support
Study: NCT02552862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Study: NCT04215432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gel containing propolis extract, nanovitamin C and nanovitamin E
Description: The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
Study: NCT02293551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Administered SC
Study: NCT01877889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
Study: NCT04295863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Standard
Description: For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Standard
Description: For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Extended
Description: For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Extended
Description: For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
Study: NCT04689971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B combination
Description: Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
Study: NCT02246608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT Standard of Care plus Oasis wound product
Description: Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine NPWT Standard of Care
Description: Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
Study: NCT02174744

Intervention type: OTHER
Intervention: numeric pain rating scale
Study: NCT02454153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REMStar Positive Airway Pressure
Description: Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LifeStyle Counseling
Description: Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
Study: NCT00478309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study: NCT00794066

Intervention type: PROCEDURE
Intervention: measuring the ankle brachial index
Description: Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de).

Intervention type: PROCEDURE
Intervention: measuring the ankle brachial index
Description: Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de).

Intervention type: PROCEDURE
Intervention: measuring the ankle brachial index
Description: Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de).
Study: NCT00800410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) services
Description: CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
Study: NCT01651091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training
Description: Psychotherapy Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual